Enrollment is complete for the randomized part of ENHANCE, a Phase 3 trial testing a new dosing schedule for Briumvi in ...
Because of how unpredictable MS symptom flares can be, columnist Desiree Lama often finds herself living a sheltered life.
Obexelimab almost completely prevented new inflammatory lesions visible on brain scans of adults with relapsing MS, per trial data.
Metis' MTS-004 was safe and eased symptoms of pseudobulbar affect in people with MS and other neurological disorders, trial data show.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback